Assembly Biosciences, Inc.
Cash Flow Statement
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||
| Net Income | $-6.1M | $-40.2M | $-61.2M | $-93.1M | $-129.9M | $-62.2M | $-97.6M | $-90.8M |
| Depreciation & Amortization | $129.0K | $129.0K | $450.0K | $498.0K | $466.0K | $691.0K | $494.0K | $643.0K |
| Depreciation | — | — | $500.0K | $500.0K | $500.0K | $700.0K | $500.0K | $600.0K |
| Amortization | — | — | — | — | — | — | — | — |
| Stock-Based Compensation | $4.7M | $3.1M | $5.1M | $6.6M | $5.2M | $21.9M | $20.6M | $28.5M |
| Net Cash from Operating Activities | $-41.1M | $-51.1M | $22.7M | $-84.5M | $-93.4M | $-63.0M | $-84.1M | $-65.0M |
| Investing Activities | ||||||||
| Capital Expenditures | $66.0K | $28.0K | $255.0K | $102.0K | $3.1M | $470.0K | $1.6M | $340.0K |
| Business Acquisitions | — | — | — | — | — | — | — | — |
| Net Cash from Investing Activities | $-113.5M | $40.2M | $-69.1M | $90.6M | $26.5M | $68.1M | $-50.3M | $-135.4M |
| Financing Activities | ||||||||
| Dividends Paid | — | — | — | — | — | — | — | — |
| Stock Repurchases | — | — | — | — | — | — | — | — |
| Net Cash from Financing Activities | $174.7M | $29.4M | $13.8M | $614.0K | $53.1M | $7.6M | $139.6M | $159.8M |
| Net Change in Cash | $20.1M | $18.5M | $-32.6M | $6.8M | $-13.8M | $12.7M | $5.3M | $-40.6M |
| Free Cash Flow | $-41.2M | $-51.1M | $22.5M | $-84.6M | $-96.5M | $-63.4M | $-85.6M | $-65.3M |